“…The following three treatment modalities were randomly allocated to all 24 defects: (a) control (empty) ( n = 8), (b) 20 mg of NBM particles (NBM; Bio‐Oss ® , S‐size, Geistlich Pharma AG) ( n = 8), and (c) 20 mg of NBM + 20 µl of EMD‐liquid ( n = 8). The sample size was chosen based on previous studies (de Brito Bezerra et al, ; Findikcioglu, Findikcioglu, Yavuzer, Elmas, & Atabay, ; Fujioka‐Kobayashi, Kobayashi, et al, ; Shim et al, ). Bilayer collagen barrier membranes (BioGide ® , Geistlich Pharma AG) in 8‐mm diameter circle was utilized to cover all defects (each group) with the rough side facing the bone defect, followed by the periosteum and skin closure with interrupted sutures in layers using 3‐0 Vicryl and 4‐0 Nylon sutures.…”